We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3179)4/24/2018 1:52:41 PM
From: Miljenko Zuanic  Respond to of 3202
Because of the good safety, I would bump dose to 300mg/day and continue to combine with anti-PD1 (overall IO), and add selected chemo (selected to cancer type). Head & Neck, maybe CRC and Ovarian, Nivo still may be good choice!??

Combination with vaccines, but delivered intra-tumoral.
ASCO may bring some more p2-chombo data from ECHO-204!